Growth Opportunity Accelevir Diagnostics is a growing Maryland biotechnology firm with a focus on ultra-rare analytes and infectious disease assays, signaling potential expansion opportunities in collaborations with biopharma partners pursuing translational research and early-stage clinical trials.

Clinical Trial Readiness The company supports biopharma from basic research through clinical trials and has active work on HIV-1 and other viral infections, indicating potential for partnerships around assay workflows that can accelerate clinical program timelines.

Funding Backing With over 15 million dollars of combined federal, state, and private funding secured and existing revenue in the multi-million range, Accelevir demonstrates financial stability that can enable co-development, grants-based collaborations, or milestone-driven deals.

Same-Day Services Recent launch of Same-Day First Morning PBMC Processing Service creates a tangible selling point for biopharma sites seeking high-quality data and faster turnaround, presenting a cross-sell opportunity to adjacent assay workflows and data services.

Tech & Platform Fit Existing tech stack and digital footprint (global cloud, CRM, e-commerce, analytics) along with partnerships with academic and pharma groups position Accelevir well for scalable, data-driven collaboration models and joint development programs.